S. S. , B. M. , G. G. , M. P. , and Y. Hf-jr, Hepatitis C screening strategies in hemodialysis patients, Am J Kidney Dis, vol.38, pp.91-97, 2001.

S. M. and V. Am, Hepatitis C virus evolutionary patterns studied through analysis of full-genome sequences, J Mol Evol, vol.54, pp.62-70, 2002.

S. A. , S. F. , L. A. , I. J. , D. Jc et al., Investigation de 22 cas de contamination par le virus de l'hépatite C dans un centre d'hémodialyse, pp.16-17, 2001.

S. Pm, T. N. , K. I. Van-hamersvelt, and . Hw, Infection control of hepatitis C in Dutch dialysis centres, Nephrol Dial Transplant, vol.13, pp.3037-3040, 1998.

S. Pm, K. I. Van-loon-am, M. D. De-coul, and . Ko, The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands : a nationwide prospective study, J Infect Dis, vol.182, pp.1291-1299, 2000.

S. N. , C. Am, L. N. , T. C. , and D. S. , A twelve year natural history of hepatitis C virus infection in hemodialyzed patients, Kidney Int, vol.46, pp.504-511, 1994.

S. Co, E. S. , G. D. , and J. Rj, Risk of death among chronic dialysis patients infected with hepatitis C virus, Am J Kidney Dis, vol.32, pp.629-634, 1998.

S. Rk, S. Aj, L. Va, S. Rt, and K. Al, Chronic hepatitis C infection in patients with end stage renal disease : characterization of liver histology and viral load in patients awaiting renal transplantation, Am J Gastroenterol, vol.94, pp.3576-3582, 1999.

S. L. , C. H. , W. A. Van-arnhem-w, and D. Beenhouwer-h, Hepatitis C virus in a hemodialysis unit : molecular evidence for nosocomial transmission

T. Ji, M. Er, A. Mj, and A. Mj, National surveillance of dialysis associated diseases in the United States, Asaio J, vol.44, pp.98-107, 1995.

T. Mj, E. Ns, R. Ar, and C. Rl, Clinical outcomes after transfusionassociated hepatitis C, N Engl J Med, vol.332, pp.1463-1466, 1995.

V. R. , F. Jl, B. J. , M. H. , and D. Pino-n, Evidence of hepatitis C virus passage across dialysis membrane, Nephron, vol.80, pp.194-196, 1998.

V. Ds, C. A. , N. A. , S. D. , and B. M. , Infections with hepatitis B and C viruses in patients on maintenance dialysis in Romania and in former communist countries : yellow spots on a blank map, J Viral Hepat, vol.7, pp.313-319, 2000.

L. P. Whelan-s and . Goldman-n, Molecular phylogenetics: state-of-the-art methods for looking into the past, Trends in Genetics, vol.17, issue.5, pp.262-272, 2001.
DOI : 10.1016/S0168-9525(01)02272-7

W. A. , M. S. , P. Nh, T. H. , and H. S. , Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney, Transplantation, vol.60, pp.642-647, 1995.

W. Ra, A. Vb, M. El, O. Ao, and E. Re, Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant, N Engl J Med, vol.341, pp.1725-1730, 1999.

Z. Jb, D. Ta, K. Ik, G. Rg, and H. Pv, The prevalence of hepatitis C virus antibodies among hemodialysis patients, Ann Intern Med, vol.112, pp.958-960, 1990.

Z. S. Scheuermann-eh, W. D. , L. Jh, and B. C. , Phylogenetic analysis of hepatitis C virus isolates from hemodialysis patients, Kidney Int, vol.49, pp.896-902, 1996.

C. Hépatite, F. Transmission-nosocomiale, A. Dm, M. J. Jm, F. Gr et al., Evidence for a cerebral effect of the hepatitis C virus, Lancet, vol.358, pp.38-39, 2001.

F. Dm, T. Hc, M. Ca, A. Jm, and F. Gr, Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease, Hepatology, vol.35, pp.433-439, 2002.

F. Dm, T. Sd, and T. Hc, Reduced quality of life in hepatitis C : is it all in the head ?, J Hepatol, vol.36, pp.435-438, 2002.

F. Gr, G. Rd, and T. Hc, Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis, Hepatology, vol.27, pp.209-212, 1998.

G. A. Schmidt-l and M. A. Fitzpatrick-r, Quality of life measurement : bibliographic study of patient assessed health outcome measures, BMJ, vol.324, p.1417, 2002.

G. Sc and C. S. , Hepatitis C : a multifaceted disease. Review of extrahepatic manifestations, Ann Intern Med, vol.123, pp.615-620, 1995.

H. C. , V. A. , B. M. , E. Mg, and B. Jm, Is hepatitis C virus infection a trigger of porphyria cutanea tarda ? Lancet, pp.788-789, 1993.

H. Rc, P. W. Hassanein, D. J. Hunt-cm, B. Bp, W. B. et al., Neuropsychological impairment in patients with chronic hepatitis C Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life, Hepatology Dig Dis Sci, vol.35, issue.42, pp.440-446, 1997.

H. Kb, M. Fontana-rj, S. Ca, . Gl, and . Sneed-pee-n, Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C, Am J Gastroenterol, vol.96, pp.2737-2744, 2001.

I. N. , I. Y. , T. E. , and T. E. Hashimoto-h, Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening, Lancet, vol.359, pp.133-135, 2002.

J. Ea, Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy, Lancet, vol.354, p.397, 1999.

K. L. , Z. Mw, H. Z. , and A. J. Barker-c, Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C, Qual Life Res, vol.9, pp.499-508, 2000.

K. Rs, Impaired health-related quality of life in chronic hepatitis C : the how, but not the why, Hepatology, vol.29, pp.277-279, 1999.

K. L. Bauer-e, F. G. , H. H. , and J. W. , Subclinical impairment of brain function in chronic hepatitis C infection, J Hepatol, vol.37, pp.349-354, 2002.

A. Kraus-mr, C. H. Schafer-a, F. H. , and M. H. , Compliance with therapy in patients with chronic hepatitis C : associations with psychiatric symptoms, interpersonal problems, and mode of acquisition, Digestive Diseases and Sciences, vol.46, issue.10, pp.2060-2065, 2001.
DOI : 10.1023/A:1011973823032

L. M. , T. Me, A. J. , and F. Gr, Hepatitis C virus infection is not associated with a marked increase in the prevalence of ophthalmic morbidity, Eye, vol.14, pp.889-891, 2000.

L. Sd, Y. S. , and S. D. Van-thiel-d, Reactivation of sarcoidosis during interferon therapy, J Gastroenterol, vol.37, pp.50-54, 2002.

L. O. , M. T. , L. Jm, C. Mp, and C. P. , Neuropathies périphériques et virus de l'hépatite C. Hépato-Gastro, pp.345-350, 2002.

M. Jg, W. Je-jr, B. Ms, P. S. , and A. Jk, The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity, J Hepatol, vol.34, pp.140-147, 2001.

M. Er, H. Je, and S. Dr, Quality of life in HCV-infection : lack of association with ALT levels, Aust N Z J Public Health, vol.25, pp.355-361, 2001.

M. Mf, F. J. Barger-sd, and M. Sb, What are quality of life measurements measuring ?, BMJ, vol.316, pp.542-545, 1998.

N. A. , A. Mm, M. S. , B. C. , and M. B. , Systemic sarcoidosis presenting as a granulomatous tattoo reaction secondary to interferonalpha treatment for chronic hepatitis C and review of the literature, Dig Dis Sci, vol.47, pp.1627-1631, 2002.

N. Mp, C. S. , B. Ms, and W. Je-jr, Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients, Semin Liver Dis, vol.19, issue.1, pp.77-85, 1999.

O. J. , H. Y. , and A. Bs, Assessment of fatigue and psychologic disturbances in patients with hepatitis C virus infection, J Clin Gastroenterol, vol.32, pp.413-417, 2001.

P. T. , G. E. , G. J. , and S. S. Longo-f, Hépatite chronique C, fatigue et métabolisme énergétique, Gastroenterol Clin Biol, vol.25, p.33, 2001.

R. Aj, D. Jp, T. G. , K. F. , and C. M. , Mesure de la qualité de vie chez des malades ayant une hépatite chronique virale C : validation d'un indicateur général et d'un indicateur spécifique. Premières données françaises, Gastroenterol Clin Biol, vol.23, pp.1296-1309, 1999.

R. Tr-3rd, C. Vm, S. M. , and K. K. , Is nausea associated with chronic hepatitis C infection ?, Am J Gastroenterol, vol.96, pp.3356-3360, 2001.

C. Hépatite, R. Transmission-nosocomiale, J. D. Aj, T. Sc, L. A. et al., The impact of diagnosis of hepatitis C virus on quality of life, Hepatology, vol.30, pp.1299-1301, 1999.

. Hépavir, première étude observationnelle d'une cohorte de malades traités par interféron alpha-2a en monothérapie. Évaluation de l'asthénie et de ses répercussions sociales, Gastroenterol Clin Biol, vol.25, pp.1061-1066, 2001.

S. Tj, D. Hickey-ar, B. Tm, and . Jr, Hepatitis C virus infection : impacts on behaviour and lifestyle, Aust N Z J Public Health, vol.22, pp.509-511, 1998.

T. Jr, K. D. , and D. M. , Health profile preferences of hepatitis C patients, Dig Dis Sci, vol.45, pp.345-350, 2000.

V. Esquer, C. , C. P. , and B. P. , Hepatitis C and fitness to work, pp.769-770, 1999.

W. Je-jr, B. Ms, M. M. , and D. Gl, Health-related quality of life in chronic hepatitis C : impact of disease and treatment response. The Interventional Therapy Group, Hepatology, vol.30, pp.550-555, 1999.

. Enfin, il faudrait recueillir des données permettant l'interprétation des résultats des études de qualité de vie en France (données de référence interpathologies , données de population générale ? qui n'existent actuellement que pour le SF-36 ?, données de référence de la population cible). L'étude et l

B. Bayliss-ms, Methods in outcomes research in hepatology : definitions and domains of quality of life, Hepatology, vol.29, pp.3-6, 1999.

B. Ms, G. B. , B. Km, S. D. , H. Ma et al., A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C, Qual Life Res, vol.7, pp.39-55, 1998.

B. M. Bobbit-ra, C. W. , and G. Bs, The Sickness Impact Profile : Development and final revision of a health status measure, Med Care, vol.19, pp.787-805, 1981.

K. L. Bernstein-d, R. Barker-cm, and G. J. Da, Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients, Hepatology, vol.343, issue.3, pp.704-708, 2002.
DOI : 10.1053/jhep.2002.31311

L. C. Bianchi-g, S. D. , A. R. , and C. Ch, Reduced quality of life in patients with chronic hepatitis C: effects of interferon treatment, Digestive and Liver Disease, vol.32, issue.5, pp.398-405, 2000.
DOI : 10.1016/S1590-8658(00)80260-1

B. Hl and W. Jm, Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group, Hepatology, vol.29, pp.264-270, 1999.

B. Hl and W. Jm, Outcomes research in chronic viral hepatitis C : effects of interferon therapy, Can J Gastroenterol, vol.14, pp.21-29, 2000.

C. Rl-jr, S. D. , and B. M. , Health assessment for chronic HCV infection : results of quality of life, Dig Dis Sci, vol.41, pp.75-80, 1996.

C. Aj, L. A. Bean-k, P. Du-chatelet-i, and V. A. , A French version of the Sickness Impact Profile (SIP) : stages in the cross cultural validation of generic quality of life scale, Fundam Clin Pharmacol, vol.6, pp.319-326, 1992.

D. Gl, B. La, S. Er, L. K. , and B. Hc-jr, Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile

D. Rc, W. R. , B. Md, B. Se, and C. Sh, Quality of life of hepatitis B and C patients after liver transplantation, Clin Transplant, vol.11, pp.282-285, 1997.

F. Bg, T. C. , and L. Kl, The impact of pegylated interferon alfa-2b on health-related quality of life in chronic hepatitis C patient (abstract), Hepatology, vol.32, p.307, 2000.

F. Rj, M. Ca, S. S. , L. Asf, and . Sneed-pee-n, Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C, Am J Gastroenterol, vol.96, pp.170-178, 2001.

K. S. Forman-l, R. I. Pien-g, and B. H. , The impact of diagnosis of hepatitis C virus on quality of life, Hepatology, vol.170, issue.4, pp.1029-1030, 2000.
DOI : 10.1053/he.2000.6026

F. Dm, T. Hc, M. Ca, A. Jm, and F. Gr, Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease, Hepatology, vol.35, pp.433-439, 2002.

F. Gr, G. Rd, and T. Hc, Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis, Hepatology, vol.27, pp.209-212, 1998.

G. B. , W. Je, A. Nk, A. J. , and A. G. , Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries : results from the IQOLA Project, J Clin Epidemiol, vol.51, pp.1149-1158, 1998.

G. T. , W. Mm, and S. N. Marino-ir, Quality of life and functional status of liver transplant recipients with recurrent viral hepatitis C, Transplant Proc, vol.31, pp.1386-1387, 1999.

H. Sm, M. Sp, and W. J. , Reliability of a population survey tool for measuring perceived health problems : a study in patients with osteoarthrosis, J Epidemiol Community Health, vol.35, pp.297-300, 1981.

H. Sm, D. J. , B. Bp, W. B. , B. U. et al., Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life, Dig Dis Sci, vol.42, pp.2482-2486, 1997.

H. Kb, M. Fontana-rj, S. Ca, . Gl, L. Sneed-pee-n et al., Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C, Am J Gastroenterol, vol.96, pp.2737-2744, 2001.

L. Galès and C. , Économie de la santé In : Mesure de la santé perceptuelle et de la qualité de vie ? méthodes et applications, LEPLÈGE A, COSTE J eds Éditions ESTEM, 2001.

C. Hépatite, L. Transmission-nosocomiale, B. C. Galès-c, C. N. , R. S. et al., Development of a preferenceweighted health status classification system in France : the Health Utilities Index 3, Health Care Manag Sci, vol.5, pp.41-51, 2002.

L. A. La-mesure-de-la-qualité-de-vie, . Puf, L. A. Coll, H. Sm-leplège-a, C. J. Leplège-a et al., Que Sais-Je ? numéro 3506 The problem of quality of life in medicine Mesure de la santé perceptuelle et de la qualité de vie ? méthodes et applications The French SF-36 Health Survey : translation, cultural adaptation and preliminary psychometric evaluation, Éditions ESTEM J Clin Epidemiol, vol.278, issue.51, pp.47-50, 1997.

M. Er, H. Je, and S. Dr, Quality of life in HCV-infection : lack of association with ALT levels, Aust N Z J Public Health, vol.25, pp.355-361, 2001.

R. Aj, J. D. , T. Sc, L. A. , and C. N. , The impact of diagnosis of hepatitis C virus on quality of life, Hepatology, vol.30, pp.1299-1301, 1999.

S. N. , G. T. , W. Mm, and M. Ir, Vulnerability to psychologic distress and depression in patients with end-stage liver disease due to hepatitis C virus, Clin Transplant, vol.11, pp.406-411, 1997.

S. N. , G. T. , W. Mm, and M. Ir, Quality of life, functional status, and depression in male liver transplant recipients with recurrent viral hepatitis C, Transplantation, vol.67, pp.69-72, 1999.

S. A. and W. Je-jr, Measuring functioning and well-being ? The Medical Outcome Study approach, 1992.

W. Je and S. Cd, The MOS 36-Item Short-Form Health Survey (SF-36

C. Hépatite, M. Transmission-nosocomiale, H. Sc, J. Fn, M. A. et al., Risk factors for acute non-A, non-B hepatitis in United States and association with hepatitis C virus infection, pp.2231-2235, 1990.

A. Mj, M. Hs, K. K. , J. Fn, and M. A. , The natural history of community-acquired hepatitis C in the United States, N Engl J Med, vol.327, pp.1899-1905, 1992.

A. Mj, C. C. , M. J. , T. D. , V. M. et al., Hepatitis C in asymptomatic blood donors The prevalence of hepatitis C virus infection in the United States, Hepatology N Engl J Med, vol.26, issue.341, pp.29-33, 1988.

A. Opendocument, A. Gl, M. Mj, M. Gm, and . Hs, Traitement de l'hépatite C. Conférence de consensus Résumé consultable sur le site : http ://www.anaes.fr/ANAES/framedef The past incidence of hepatitis C virus infection : implications for the future burden of chronic liver disease in the United States, ANAES Hepatology, vol.31, pp.777-782, 2000.

A. Nl, L. Jr, E. J. , R. J. Bennett-wg, I. Y. et al., Liver transplantation for hepatitis C virusrelated cirrhosis Estimates of the costeffectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C, Hepatology Ann Intern Med, vol.20, issue.127, pp.24-27, 1994.

B. C. , J. F. , L. D. , G. G. , and Z. Km, Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe : results of a European concerted action, J Hepatol, vol.29, pp.173-183, 1998.

C. E. , K. Jj, H. Sm, J. Jk, and J. E. , Prognostis after the first episode of gastrointestinal bleeding or coma in cirrhosis : survival and prognostic factors, Scand J Gastroenterol, vol.24, pp.999-1006, 1989.

D. F. , C. C. , G. , F. Jp, and D. C. , Hepatitis C virus related cirrhosis : time to occurrence of hepatocellular carcinoma and death, Gut, vol.47, pp.131-136, 2000.

D. Km, B. Sh, and L. M. , Liver transplantation for chronic viral hepatitis, Viral Hepatol Rev, vol.2, pp.219-228, 1996.

D. S. , B. L. , P. T. , and V. Aj, Modeling the HCV epidemic in France, Hepatology, vol.29, pp.1596-1601, 1999.

C. Hépatite, D. Transmission-nosocomiale, W. Jb, C. D. Valleron-aj, and D. Jf, Comparing the Public Health burden of chronic hepatitis C and HIV infection in France, 2003.

D. F. , D. Jc, M. N. , and G. A. , Hepatitis C in a French population-based survey, 1994 : Seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group Consensus Statement. European Association for the Study of the Liver, EASL International Consensus Conference on Hepatitis C. Paris, pp.1490-1496, 1997.

E. Hb, M. Ac, and K. C. , Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States, Hepatology, vol.33, pp.62-65, 2001.

K. Ve, K. H. , and W. Re, An analysis of liver transplant experience from 37 transplant centers as reported to Medicare, pp.554-561, 1993.

L. Mg, Modelling the hepatitis C virus epidemic in Australia, J Gastroenterol Hepatol, vol.14, pp.1100-1107, 1999.

M. M. , M. Jg, G. Sc, R. Vk, and S. M. , Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C : a randomised trial, Lancet, vol.358, pp.958-965, 2001.

O. J. , L. Jm, and S. H. , Progression and natural history of chronic hepatitis B and C, Leber Magen Darm, vol.25, pp.205-210, 1995.

R. T. , H. R. , K. Md, P. Jk, and S. M. , Estimating the number of blood transfusion recipients infected by hepatitis C virus in Canada, 1960-85 and 1990-92, 1998.

R. Aj, T. J. , T. Sc, J. D. , and M. Am, Assessment of long-term outcomes of hepatitis C virus infection in a cohort of patients with acute hepatitis in 1971-1975 : results of a pilot study, J Gastroenterol Hepatol, vol.14, pp.269-273, 1999.

R. , B. A. , P. Jm, D. D. , and A. Jc, Epidemiological factors affecting the severity of hepatitis C virus-related liver disease : a French survey of 6,664 patients, Hepatology, vol.26, pp.485-490, 1997.

S. M. , R. El, M. B. , and W. Jb, Simulation of hepatitis C based on a mandatory reporting system, Eur J Gastroenterol Hepatol, vol.14, pp.25-34, 2002.

B. G. Salerno-f, M. P. , B. S. , and C. L. , Survival and prognostic factors of cirrhotic patients with ascites : a study of 134 outpatients, Am J Gastroenterol, vol.88, pp.514-519, 1993.

S. J. Weinstein-js, H. Jk, and G. Sj, Empirically calibrated model of hepatitis C virus infection in the United States, Am J Epidemiol, vol.156, pp.761-773, 2002.

S. Lb, B. , W. Ec, D. Sj, and A. Hj, Long-term mortality after transfusion-associated non-A, non-B hepatitis, N Engl J Med, vol.327, pp.1906-1911, 1992.

. Soto-b, R. L. Sanchez-quijano-a, D. Olmo, J. , and G. Am, Human immunodeficiency virus infection modified the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis, Journal of Hepatology, vol.26, issue.1, pp.1-5, 1997.
DOI : 10.1016/S0168-8278(97)80001-3

T. Veterans, A. Variceal, and . Group, Sclerotherapy for male alcoholic cirrhotic patients who have bled from eosophageal varices : results of a randomized, multicenter clinical trial, Hepatology, vol.20, pp.618-625, 1994.

T. F. , C. C. , A. A. Drago-c, and T. A. , Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis, J Hepatol, vol.16, pp.273-281, 1992.

W. J. , M. Gm, M. Jg, and P. T. , Estimating future hepatitis C morbidity, mortality, and costs in the United States, Am J Public Health, vol.90, pp.1562-1569, 2000.

Y. M. Nakano-y, T. E. , S. T. , and K. K. , Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up, Scand J Gastroenterol, vol.27, pp.812-816, 1992.

Z. S. , T. M. , and E. Saadany-s, Prediction of hepatitis C burden in Canada, Can J Gastroenterol, vol.14, pp.575-580, 2000.

C. Hépatite, . Transmission-nosocomiale, B. État-de-santé-et-devenir-des-personnes-atteintes, P. Jr, and . Sg, The Markov process in medical prognosis, Med Decis Making, vol.3, pp.419-458, 1983.

B. Wg, I. Y. , B. J. , W. Jb, P. Sg et al., Estimates of the cost-effectiveness of a single course of interferon alpha2b in patients with histologically mild chronic hepatitis C, Ann Intern Med, vol.127, pp.855-865, 1997.

F. T. Berger-k and S. Td, Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective, European Journal of Cancer, vol.34, issue.12, pp.1894-1901, 1998.
DOI : 10.1016/S0959-8049(98)00260-3

B. Wb and K. Ma, On the economic foundations of CEA. Ladies and gentlemen, take your positions, J Health Econ, vol.19, pp.439-459, 2000.

B. Mp, K. Jj, K. Sh, L. Sr, A. Jp et al., Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study, Transfusion, vol.35, pp.903-910, 1995.

B. Mm, C. A. , F. L. , W. Jb, and E. Dr, Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C, J Hepatol, vol.33, pp.651-658, 2000.

C. Ql, W. Kuo-g, O. Aj, B. Lp, . Dw et al., Isolation of cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome, Science, vol.244, pp.359-362, 1989.

C. Am, B. C. Barin-f, L. F. , M. P. , M. M. et al., A comparative evaluation of the sensitivity of seven anti-hepatitis C virus screening tests, Vox Sang, vol.69, pp.213-216, 1995.

D. Koning-hj, . Van-ineveld, . Bm, . Van-oortmarssen-gj, C. De-haes-jc et al., Breast cancer screening and cost-effectiveness; Policy alternatives, quality of life considerations and the possible impact of uncertain factors, International Journal of Cancer, vol.66, issue.4, pp.531-537, 1991.
DOI : 10.1038/bjc.1987.112

D. Jc, D. F. , C. F. , P. J. , and R. , Estimation du nombre de sujets infectés par le VHC en France, pp.1994-95, 1996.

D. S. , P. T. , and V. Aj, Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe, J Viral Hepat, vol.6, pp.411-413, 1999.

D. F. , S. Lr, L. , H. C. , and P. P. , Cost-benefit analysis of screening strategies by human immunodeficiency virus in French blood donor, Transfus Clin Biol, vol.6, pp.180-188, 1999.

D. Edlin-r, Is it really possible to build a bridge between cost-benefit analysis and cost-effectiveness analysis ? J Health Econ, pp.827-843, 2002.

D. M. , S. G. , T. G. , and O. Brien-b, Méthodes d'évaluation économique des programmes de santé, Economica, 1998.

G. Jy, L. H. , Y. C. , C. Sc, and C. Wl, Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients, Nephron, vol.69, pp.459-465, 1995.

J. C. , C. Am, L. Barin-f, T. C. , and B. C. , Screening tests of anti-HVC antibodies used in France. Analysis of sensitivity, Transfus Clin Biol, vol.1, pp.295-301, 1994.

C. Hépatite, Transmission nosocomiale, état de santé et devenir des personnes atteintes JOHANNESSON M. On aggregating QALYs : a comment on Dolan, J Health Econ, vol.18, pp.381-386, 1999.

J. E. , V. C. , K. D. , and L. Gales, Analyse coût-efficacité du traitement de l'hépatite chronique C, Gastroenterol Clin Biol, vol.20, pp.958-967, 1996.

J. Jf and C. C. , Cost-effectiveness analysis of strategies for hepatitis C screening in French blood recipients, Eur J Public Health, vol.11, pp.373-379, 2001.

K. Jh, L. M. Hwang-yt, Y. Pm, and C. Pj, Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay. A clinicopathologic study and demonstration of the usefulness of a third-generation assay, Dig Dis Sci, vol.41, pp.161-165, 1996.

K. S. , R. L. Bacon-b, G. J. , and R. V. , Performance characteristics and results of a large-scale screening program for viral hepatitis and risk factors associated with exposure to viral hepatitis B and C : results of the national hepatitis screening survey, Hepatology, vol.24, p.979, 1996.

K. Wr, P. Jj, T. Tm, and D. Er, Cost-effectiveness of 6 and 12 months of interferon alpha therapy for chronic hepatitis C, Ann Intern Med, vol.127, pp.866-874, 1997.

L. K. , J. A. Sugano-d, W. C. , and C. W. , Hepatitis C infection risk analysis : who should be screened ? Comparison of multiple screening strategies based on the National hepatitis surveillance group, Am J Gastroenterol, vol.93, pp.591-596, 1998.

L. Kl, T. C. , H. T. , S. Ml, and G. Sc, A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C, Hepatology, vol.34, pp.395-403, 2001.

L. S. , R. M. , and M. Jp, Prevention could be less cost-effective than cure : the case of HCV screening policies in France, Int J Technol Assess Health Care, 2003.

L. F. , M. M. , C. P. , D. La-croix-i, H. Jm et al., Comparative study of conventional and novel strategies for the detection of hepatitis C virus RNA in serum : amplicor, branched-DNA, NASBA and in-house PCR, J Virol Methods, vol.54, pp.159-171, 1995.

M. P. , M. V. , G. C. , H. P. , and C. R. Czernichow-p, Efficience comparée de trois stratégies de prise en charge de l'hépatite chronique C : influence sur le risque de cirrhose à 8 ans, Gastroenterol Clin Biol, vol.20, pp.47-54, 1996.

M. Ra, J. M. Cullen-rw, and B. F. , Hepatitis B virus vaccine. Cost-benefit analysis of its use in children's hospital. Clinical Pediatr, pp.359-365, 1989.

M. Jp, A. P. , L. Coroller-ag, and M. , QALYS or not QALYS : that is the question ? Rev Epidemiol Sante Publique, pp.573-583, 1995.

A. Aspects-médico-Économiques-du-dépistage-et-du-traitement-213 and S. C. Pereira-a, A model of the health and economic impact of posttransfusion hepatitis C : application to cost-effectiveness analysis of further expansion of HCV screening protocols, Transfusion, vol.40, pp.1182-1191, 2000.

P. T. Bedossa and O. P. , Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups, Lancet, vol.349, pp.825-832, 1997.

R. Kr, W. Tl, P. Pj, and S. M. Everson-g, Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C, Hepatology, vol.33, pp.433-438, 2001.

R. M. , L. S. , N. J. , B. M. , H. P. et al., Analyse socioéconomique de différentes stratégies de dépistage de l'hépatite chronique C dans la population française, Gastroenterol Clin Biol, vol.20, pp.33-40, 1997.

S. S. , B. M. , G. G. , M. P. , and Y. Hf-jr, Hepatitis C screening strategies in hemodialysis patients, Am J Kidney Dis, vol.38, pp.91-97, 2001.

S. M. , W. Jb, M. B. , and R. El, A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C, Eur J Gastroenterol Hepatol, vol.13, pp.483-438, 2001.

S. J. , W. Mc, H. Jk, and G. Sj, Empirically calibrated model of hepatitis C virus infection in the United States, Am J Epidemiol, vol.156, pp.761-773, 2002.

S. K. , R. O. , H. R. , W. Jb, and J. D. , Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden, Scand J Gastroenterol, vol.36, pp.870-876, 2001.

S. P. Donaldson-c, Should we use willingness to pay to elicit community preferences for health care ? New evidence from using a 'marginal' approach, J Health Econ, vol.21, pp.971-991, 2002.

S. A. and B. A. Farrell-g, The cost-effectiveness of alpha interferon in the treatment of chronic active hepatitis C, Med J Aust, vol.160, pp.268-272, 1994.

S. A. Brown-s and F. Cg, Hepatitis C : an economic evaluation of extended treatment with interferon, Med J Aust, vol.171, pp.189-193, 1999.

S. A. Law-m, The cost of hepatitis C and the cost-effectiveness of its prevention, Health Policy, vol.58, pp.121-131, 2001.

S. U. Sroczynski-g, R. S. , W. J. , and R. Bm, Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C, Gut, vol.52, pp.425-432, 2003.

R. W. Stein-k and W. J. , Cost effectiveness of combination therapy for hepatitis C: a decision analytic model, Gut, vol.50, issue.2, pp.253-258, 2002.
DOI : 10.1136/gut.50.2.253

C. Hépatite, S. L. Transmission-nosocomiale, C. H. , W. A. Van-arnhem-w, and D. Beenhouwer-h, Hepatitis C virus in a hemodialysis unit : molecular evidence for nosocomial transmission, Kidney Int, vol.49, pp.889-895, 1996.

W. Jb, P. T. , L. Mh, A. Jk, and P. Sg, Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group, Am J Gastroenterol, vol.95, pp.1524-1530, 2000.

Y. Y. , G. Sj, P. Ad, L. E. , and C. L. , Prevention of human immunodeficiency virus-related opportunistic infections in France : a costeffectiveness analysis, Clin Infect Dis, vol.36, pp.86-96, 2003.

Y. Zm, M. Singer-me, S. Jg, and . Km, Cost effectiveness of interferon alpha-2b combined with ribavirin for the treatment of chronic hepatitis C, Hepatology, vol.30, pp.1318-1324, 1999.

. Excepté-chirurgie-obstétricale, chirurgie gynéco-obstétrique pour les femmes uniquement ; 3 : résultats en analyse bivariée